Dr Longway Tsai, MD | |
12225 South St, Ste 101, Artesia, CA 90701-7046 | |
(562) 865-4141 | |
(562) 865-6621 |
Full Name | Dr Longway Tsai |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 12225 South St, Artesia, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265438113 | NPI | - | NPPES |
00A343950 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | A34395 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Longway Tsai, MD 12225 South St, Ste 101, Artesia, CA 90701-7046 Ph: (562) 865-4141 | Dr Longway Tsai, MD 12225 South St, Ste 101, Artesia, CA 90701-7046 Ph: (562) 865-4141 |
News Archive
Earlier evidence out of UCLA suggested that meditating for years thickens the brain (in a good way) and strengthens the connections between brain cells. Now a further report by UCLA researchers suggests yet another benefit.
The Congressional Republicans who brought us the mindless budget cuts known as the sequester have shown remarkable indifference to life-sustaining government services, American jobs and other programs.
A new patient resource has launched in the UK offering primary care healthcare professionals (HCPs) the opportunity to help patients self-care for their wounds and minimise scarring.
After decades of focusing on the management of respiratory failure, circulatory shock and severe infections that lead to extended stays in hospital intensive care units, critical care researchers are increasingly turning attention to what they believe is a treatable complication developed by many who spend days or weeks confined to an ICU bed: debilitating muscle weakness that can linger long after hospital discharge.
Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
› Verified 7 days ago